MET protein levels show promise as biomarker for aggressive colon cancer
MET protein levels correlate strongly with epithelial-mesenchymal
transition (EMT) phenotype, a treatment-resistant type of colorectal
cancer and may be used as a surrogate biomarker, according to new
research from The University of Texas MD Anderson Cancer Center.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Epithelial Cancer | Texas University